NICE Endorses Talazoparib Enzalutamide for Pros...

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide ...
EU Medicine Authorizations 2025: A Milestone for Innovation and Accessibility
Empowering Leaders at the Global Pharma Executive Course: Navigating Industry...
Johnson & Johnson’s EMA Application for Teclistamab Daratumumab Th...
Biomanufacturing Excellence Act: Strengthening U.S. Biopharmaceutical Manufac...
Health Investment Returns: Harnessing Health as a Strategic Economic Asset
Interchangeable Biosimilar Approval: FDA Greenlights Poherdy as First to Perjeta
Koselugo EU Approval: A Milestone in Treating Plexiform Neurofibromas for Adu...
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
Datroway TNBC Therapy: Transforming First-Line Treatment for Metastatic Tripl...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications
Biosimilars Market Trends 2025: Understanding Erosion and Growth
Transforming Cancer Treatment: Implications of Subcutaneous Pembrolizumab App...